Latest news with #ZYUSLifeSciencesCorporation
Yahoo
22-05-2025
- Business
- Yahoo
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
Paving the way for evidence-based solutions in cancer pain management with its lead drug product, Trichomylin® softgel capsules SASKATOON, Saskatchewan, May 22, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial. The Phase 2 UTOPIA clinical trial will consist of Phase 2A ("UTOPIA-1") and Phase 2B ("UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population. Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025. ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a "strong consensus" supporting cannabinoids for managing cancer-related symptoms. While researchers highlight the need for further research to assess the full therapeutic potential of cannabinoids, the findings signal a critical shift in the scientific conversation. This emerging body of evidence reinforces the importance of rigorous clinical research, product purity and consistency, and reinforces ZYUS' commitment to advancing evidence-based cannabinoid therapies. "As we finalize site initiation for UTOPIA-1, we are proud to advance clinical development of Trichomylin® softgel capsules," said Brent Zettl, President and CEO of ZYUS. "Our research aims to bridge the gap between conventional treatments like opioids and NSAIDs, and deliver an alternative, evidence-based pharmaceutical option for cancer pain. This trial is a pivotal step in our journey to improve patient outcomes and quality of life." About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2, begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2 begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025 are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. View source version on Contacts For more information, please contact: ZYUS Media Inquiriesmedia@ 1-833-651-7723 ZYUS Investor Relationsinvestors@
Yahoo
16-05-2025
- Business
- Yahoo
ZYUS Life Sciences Announces Closing of Unit Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, May 16, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press releases dated May 1 and May 6, 2025, it has closed the second and final tranche (the "Second Tranche") of its non-brokered private placement (the "Offering") of units of the Company (each a "Unit") through the issuance of a further 871,212 Units for gross proceeds of $574,999.92. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on May 6, 2025) (the "First Tranche") is approximately $1.37 million. The Company issued a total of 2,083,333 Units each priced at $0.66 per Unit in the Offering. Each Unit consists of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.94 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025 and all securities issued under the Second Tranche are subject to a hold period expiring September 16, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the "TSXV"). The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance and use of proceeds from the Private Placement. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, the Company's ability to obtain TSXV final acceptance and use of proceeds from the Private Placement are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. View source version on Contacts For more information:ZYUS Media Inquiriesmedia@ 1-833-651-7723 ZYUS Investor Relationsinvestors@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-04-2025
- Business
- Yahoo
ZYUS Life Sciences Corporation Announces Issuance of Bonus Warrants Pursuant to Loan Agreements
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, April 11, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announces that it has received conditional acceptance from the TSX Venture Exchange (the "Exchange") to issue certain common share purchase warrants to independent directors of the Company ("Lenders") in connection with the issuance and amendment of certain unsecured loans announced in its previous press releases of March 10, 2025 and March 17, 2025. As previously announced on March 10, 2025, unsecured loans between the Company and one of its independent directors entered on October 1, November 5 and December 20, 2024 (the "Prior Unsecured Loans") had their maturity dates of April 1, May 5, and June 20, 2025, respectively, extended to March 28, 2027. Additionally, the director also advanced an additional unsecured loan ("Loan 1") to the Company in the amount of CAD$1,500,000. In exchange for amending the maturity dates of the Prior Unsecured Loans and advancing Loan 1, the director received an aggregate of 4,875,000 common share purchase warrants having an expiry date of April 11, 2027, subject to the acceleration conditions described in the Company's March 10, 2025 press release. Each warrant entitles the director to acquire one common share of the Company at an exercise price of $0.80 per common share until the expiry date. The warrants and any shares issuable on exercise thereof are subject to a statutory hold period expiring on August 12, 2025 in accordance with applicable Canadian securities law. As announced on March 17, 2025, a promissory note agreement having a maturity date of August 27, 2025 (the "Promissory Note") previously entered between the Company's wholly-owned subsidiary, ZYUS Life Sciences Inc., and a second independent director of the Company was amended and replaced by a loan agreement ("Loan 2") between the Company and the director. Pursuant to Loan 2, this director advanced to the Company additional cash consideration of $0.25 million and $0.025 million of accrued but unpaid interest under the Promissory Note was capitalized and added to the principal amount of Loan 2 for a total of $0.375 million, increasing the principal amount owing to the director from $0.1 million to $0.375 million and extending the maturity date from August 27, 2025 to March 28, 2027. In exchange for extending the maturity date and advancing additional cash consideration, the director received an aggregate of 281,250 common share purchase warrants having an expiry date of April 11, 2027, subject to the acceleration conditions described in the Company's March 17, 2025 press release. Each warrant entitles the director to acquire one common share of the Company at an exercise price of $0.80 per common share until the expiry date. The warrants and any shares issuable on exercise thereof are subject to a statutory hold period expiring on August 12, 2025 in accordance with applicable Canadian securities law. The issuance of warrants constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as lenders are each directors of the Company. The Company has relied on the exemption from the valuation requirement pursuant to section 5.5(b) (Issuer Not Listed on Specified Markets) of MI 61-101 and from the minority shareholder approval requirement prescribed by section 5.7(1)(a) (Fair Market Value Not More Than 25 Percent of Market Capitalization) of MI 61-101 respecting issuance of the warrants. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X (formerly known as Twitter) @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids and acceleration of the exercise period of the warrants. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, and introduce products that act as alternatives to current pain management therapies such as opioids, and acceleration of the exercise period of the warrants are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. View source version on Contacts ZYUS Media Inquiriesmedia@ 1-833-651-7723 ZYUS Investor Relationsinvestors@ Sign in to access your portfolio
